Abstract: SA-PO366

Proton Pump Inhibitors and Risk of CKD: A Meta-analysis

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 301 CKD: Risk Factors for Incidence and Progression

Authors

  • Wijarnpreecha, Karn, Bassett Medical Center, Cooperstown, New York, United States
  • Cheungpasitporn, Wisit, Mayo Clinic, Rochester, Minnesota, United States
  • Chesdachai, Supavit, Mahidol University, Bangkok, Thailand
  • Panjawatanan, Panadeekarn, Chiang Mai University, Chiangmai, Thailand
  • Thongprayoon, Charat, Bassett Medical Center, Cooperstown, New York, United States
Background

Proton pump inhibitors (PPIs) are one of the most commonly prescribed medications worldwide. Recent studies have raised a concern over increased risk of chronic kidney disease (CKD) or end-stage renal disease (ESRD) among PPIs users but the results of those studies were inconsistent. This meta-analysis was conducted to summarize all available data and to estimate this potential association.

Methods

A comprehensive literature review was conducted using MEDLINE and EMBASE database through March 2017 to identify all studies that reported the risk of CKD or ESRD among PPIs users compared with non-PPI users were included. Adjusted point estimates from each study were combined by the generic inverse variance method of DerSimonian and Laird.

Results

Of 8,950 studies, five studies (three cohort studies and two case-control studies) with 536,902 participants met the eligibility criteria and were included in the meta-analysis. We found that individuals with PPIs use had significantly increased the risk of CKD or ESRD when compared with non-PPIs users (pooled RR of 1.33, 95% CI, 1.18-1.51). There was no publication bias of overall included studies assessed by the funnel plots.

Conclusion

This study demonstrated an increased risk of CKD or ESRD among PPIs users. Whether this association is causal requires further investigations.

Forest plot